Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 342

1.

Pathway-based identification of biomarkers for targeted therapeutics: personalized oncology with PI3K pathway inhibitors.

Andersen JN, Sathyanarayanan S, Di Bacco A, Chi A, Zhang T, Chen AH, Dolinski B, Kraus M, Roberts B, Arthur W, Klinghoffer RA, Gargano D, Li L, Feldman I, Lynch B, Rush J, Hendrickson RC, Blume-Jensen P, Paweletz CP.

Sci Transl Med. 2010 Aug 4;2(43):43ra55. doi: 10.1126/scitranslmed.3001065.

PMID:
20686178
[PubMed - indexed for MEDLINE]
Free Article
2.

Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs.

Ogita S, Lorusso P.

Target Oncol. 2011 Jun;6(2):103-17. doi: 10.1007/s11523-011-0176-7. Epub 2011 May 6. Review.

PMID:
21547565
[PubMed - indexed for MEDLINE]
3.

Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy.

Coughlin CM, Johnston DS, Strahs A, Burczynski ME, Bacus S, Hill J, Feingold JM, Zacharchuk C, Berkenblit A.

Breast Cancer Res Treat. 2010 Nov;124(1):1-11. doi: 10.1007/s10549-010-1108-4. Epub 2010 Aug 28. Review.

PMID:
20803067
[PubMed - indexed for MEDLINE]
4.

Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.

McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M.

Adv Enzyme Regul. 2006;46:249-79. Epub 2006 Jul 18.

PMID:
16854453
[PubMed - indexed for MEDLINE]
5.

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma.

Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL.

PLoS Med. 2008 Jan 22;5(1):e8. doi: 10.1371/journal.pmed.0050008.

PMID:
18215105
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Targeting phosphoinositide 3-kinase: moving towards therapy.

Marone R, Cmiljanovic V, Giese B, Wymann MP.

Biochim Biophys Acta. 2008 Jan;1784(1):159-85. Epub 2007 Oct 12. Review.

PMID:
17997386
[PubMed - indexed for MEDLINE]
Free Article
7.

Expression of proline-rich Akt-substrate PRAS40 in cell survival pathway and carcinogenesis.

Huang B, Porter G.

Acta Pharmacol Sin. 2005 Oct;26(10):1253-8.

PMID:
16174443
[PubMed - indexed for MEDLINE]
Free Article
8.

The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.

Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF.

Curr Cancer Drug Targets. 2008 May;8(3):187-98. Review.

PMID:
18473732
[PubMed - indexed for MEDLINE]
9.

Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.

Dan S, Okamura M, Seki M, Yamazaki K, Sugita H, Okui M, Mukai Y, Nishimura H, Asaka R, Nomura K, Ishikawa Y, Yamori T.

Cancer Res. 2010 Jun 15;70(12):4982-94. doi: 10.1158/0008-5472.CAN-09-4172. Epub 2010 Jun 8.

PMID:
20530683
[PubMed - indexed for MEDLINE]
Free Article
10.

PTEN regulates angiogenesis through PI3K/Akt/VEGF signaling pathway in human pancreatic cancer cells.

Ma J, Sawai H, Ochi N, Matsuo Y, Xu D, Yasuda A, Takahashi H, Wakasugi T, Takeyama H.

Mol Cell Biochem. 2009 Nov;331(1-2):161-71. doi: 10.1007/s11010-009-0154-x. Epub 2009 May 13.

PMID:
19437103
[PubMed - indexed for MEDLINE]
12.

Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer.

Hernandez-Aya LF, Gonzalez-Angulo AM.

Oncologist. 2011;16(4):404-14. doi: 10.1634/theoncologist.2010-0402. Epub 2011 Mar 15. Review.

PMID:
21406469
[PubMed - indexed for MEDLINE]
Free PMC Article
13.
15.

Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway.

Granville CA, Memmott RM, Gills JJ, Dennis PA.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):679-89. Review.

PMID:
16467077
[PubMed - indexed for MEDLINE]
Free Article
16.

The PKB/AKT pathway in cancer.

Carnero A.

Curr Pharm Des. 2010 Jan;16(1):34-44. Review.

PMID:
20214616
[PubMed - indexed for MEDLINE]
17.

Activation of PI3K-Akt signaling pathway promotes prostate cancer cell invasion.

Shukla S, Maclennan GT, Hartman DJ, Fu P, Resnick MI, Gupta S.

Int J Cancer. 2007 Oct 1;121(7):1424-32.

PMID:
17551921
[PubMed - indexed for MEDLINE]
18.

PTEN, more than the AKT pathway.

Blanco-Aparicio C, Renner O, Leal JF, Carnero A.

Carcinogenesis. 2007 Jul;28(7):1379-86. Epub 2007 Mar 6. Review.

PMID:
17341655
[PubMed - indexed for MEDLINE]
Free Article
19.

Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor.

Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chène P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, García-Echeverría C, Sellers WR, Voliva CF.

Mol Cancer Ther. 2012 Feb;11(2):317-28. doi: 10.1158/1535-7163.MCT-11-0474. Epub 2011 Dec 21.

PMID:
22188813
[PubMed - indexed for MEDLINE]
Free Article
20.

Analysis of complex protein kinase B signalling pathways in human prostate cancer samples.

Jendrossek V, Henkel M, Hennenlotter J, Vogel U, Ganswindt U, Müller I, Handrick R, Anastasiadis AG, Kuczyk M, Stenzl A, Belka C.

BJU Int. 2008 Aug;102(3):371-82. doi: 10.1111/j.1464-410X.2008.07703.x. Epub 2008 May 12.

PMID:
18476967
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk